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Potential of MMP-9 based 
nanoparticles at optimizing the cow 
dry period: pulling apart the effects 
of MMP-9 and nanoparticles
L. Gifre-Renom1, J. V. carratalá2, S. Parés1, L. Sánchez-García2, n. ferrer-Miralles2,3,4, 
A. Villaverde2,3,4, A. Bach1,5, elena Garcia-Fruitós1 ✉ & Anna Arís1 ✉
The cow dry period is a non-milking interval where the mammary gland involutes and regenerates 
to guarantee an optimal milk production in the subsequent lactation. Important bottlenecks such 
as the high risk of intramammary infections complicate the process. Antibiotics have been routinely 
used as a preventive treatment but the concerns about potential antibiotic resistance open a new 
scenario in which alternative strategies have to be developed. Matrix metalloproteinase-9 (MMP-9) is 
an enzyme able to degrade the extracellular matrix, triggering the involution and immune function of 
cow mammary gland. We have studied the infusion into the mammary gland of MMP-9 inclusion bodies 
as protein-based nanoparticles, demonstrating that 1.2 mg of MMP-9 enhanced the involution and 
immune function of the cow mammary gland. However, the comparison of the effects triggered by the 
administration of an active and an inactive form of MMP-9 led to conclude that the response observed 
in the bovine mammary gland was mainly due to the protein format but not to the biological activity of 
the MMP-9 embedded in the inclusion body. This study provides relevant information on the future use 
of protein inclusion bodies in cow mammary gland and the role of MMP-9 at dry-off.
The dry period is crucial to optimize milk production in dairy cattle1. During this period, the mammary gland 
regresses and, after that, it proliferates and differentiates to allow optimal milk production in the subsequent 
lactation. However, the presence of galactopoietic hormones due to a concomitant pregnancy does not facilitate 
the beginning of involution and delays the activation of the immune system, which orchestrates all this process2. 
Moreover, the high amount of milk accumulated in the mammary gland at dry-off exert high intra-mammary 
pressure and may lead to milk leakage, which in turn maintains the teat canal opened and full of nutrients, 
increasing the risk of a pathogen invasion3. When activated, the immune system recruits macrophages and neu-
trophils, which could fight against a possible infection4. Yet their phagocytic activity against pathogens is dimin-
ished at dry-off, as phagocytes are engaged at engulfing milk fat, cell debris, and other compounds derived from 
milk and accumulated in the mammary gland4. To reduce the risk of mastitis, antibiotics are infused routinely 
into the mammary gland at dry-off. However, the preventive use of antibiotics has raised concerns about the 
emergence of antibiotic resistances. In this context, there is a need to find new strategies to boost the immune 
system of the mammary gland and its involution at dry-off.
Recently, new strategies based on the use of matrix metalloproteinase-9 (MMP-9) have been studied 
mainly to modulate infiltration of immune cells and involution at dry-off. Matrix metalloproteinase-9 is a 
tissue-remodelling enzyme that degrades the extracellular matrix (ECM) and, in the mammary gland, is phys-
iologically released by mammary epithelial cells and neutrophils entering into the tissue during the involution 
process5,6. It has been previously demonstrated that the proteolytic degradation of the ECM is a key factor during 
the loss of differentiation of mammary epithelial cells and the induction of apoptosis and involution7. Hence, in a 
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previous work we hypothesized that exogenous administration of a recombinant MMP-9 (rMMP-9), which was 
not sensible to tissue inhibitors of metalloproteinases 1 and 3 (TIMP1 and TIMP3), could represent a strategy 
to accelerate tissue involution at dry-off. The administration of rMMP-9 into the mammary gland at dry-off was 
tested8 using two recombinant protein formats: a soluble form, and a nanoparticulated format, also known as 
inclusion body (IB). Inclusion bodies are protein-based nanoparticles of few hundred nanometers formed during 
recombinant protein production processes9 showing a clear biomedical potential10. Parés et al. (2017) reported 
an increase in the local immune response and mammary involution when administering rMMP-9 as an IB at 
dry-off in dairy cows, whereas the administration of rMMP-9 in a soluble form only increased the endogenous 
MMPs without affecting general parameters of immune stimulation and mammary involution markers8. These 
findings encouraged us to elucidate whether the observed effects of rMMP-9 IBs in the bovine mammary gland 
were due to a different performance of rMMP-9 embedded in the nanoparticles compared with a soluble form, 
or due to the effect of the nanoparticle or IB format itself. For this, we have determined in vivo, first, the lowest 
dose of rMMP-9 IBs that boost innate immunity and mammary involution, and second, whether this was due to 
the nanoparticle format or to the inherent properties of the rMMP-9 comprised in these IBs11. Through the com-
parison of the effects triggered by the administration of an inactive form of rMMP-9 IB at dry-off with its active 
counterpart, the real potential of rMMP-9 IBs during the cow dry period has been distinguished.
Results and Discussion
Determining the minimal inflammatory dose of rMMP-9 nanoparticles. The greatest tested dose 
(12 mg) of MMP-9 IBs at dry-off was previously reported by Parés et al. (2017) as a potent immunostimulator of 
the bovine mammary gland8. Herein, in Exp. 1, three lower doses were evaluated along with the 12-mg dose. All 
used doses enhanced the recruitment of immune cells into mammary gland (namely SCC) up to 6 d post dry-off 
(Fig. 1a). At day 9, the myeloid cells recruited in the controls started to rise but were still below those obtained 
with the 12- and 6-mg doses (Fig. 1a). Lactoferrin synthesis, whose rise is also associated with an augmented 
immune activity12, increased at day 1 after dry-off until day 3 in all the tested doses (Fig. 1b). The involution 
markers BSA and Na+/K+, whose increase reflects the disruption of tight junction and the mixture of blood com-
ponents in milk secretion13, followed similar patterns as lactoferrin with a marked increase at day 1 after infusions 
(Fig. 1c,d). For all doses tested in Exp. 1 there was a shift in the levels of the analysed parameters at day 1 and these 
values were kept above controls until day 3 or day 6 for BSA and Na+/K+, respectively (Fig. 1c,d). Importantly, 
this experiment replicated the results observed by Parés et al. (2017)8, consolidating the potential of rMMP-9 IBs 
Figure 1. Mammary gland involution markers analysed from mammary gland secretions for the tested doses 
(0 –control–, 1.2, 3, 6, and 12 mg) of inclusion bodies containing matrix metalloproteinase-9 along 0, 1, 3, 6, 
and 9 d post-infusion. Non-transformed means and SEM (error bars) are represented while P-values were 
obtained from transformed data, when necessary. Asterisks depict significant differences between treatments 
and the control group within time. (a) Somatic cell counts (SCC) are expressed in million (106) cells per mL (M 
cells/ml); P < 0.0001. (b) Lactoferrin (LF); P < 0.0001. (c) Bovine serum albumin (BSA); P < 0.0001. (d) Na+/
K+ ratio; P < 0.0001. For differences between different treatments within each time point, see Table S1 in the 
Supplementary Material.
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to locally stimulate the recruitment of immune cells in the mammary gland at dry-off and to accelerate the onset 
of involution biomarkers after 24 h of infusions.
Since all the tested doses in Exp. 1 (Fig. 1) induced similar effects during the week following dry-off, either 
regarding the immune stimulation or involution parameters, Exp. 2 was conducted to test lower doses of rMMP-9 
IBs (Fig. 2). In this case, there was a lack of effect of low doses only observing a slight increase over control quar-
ters with 0.12 mg (Fig. 2). Given that the minimum amount of rMMP-9 IBs eliciting a clear immunostimulating 
effect in the mammary gland was 1.2 mg (Fig. 2), this dose was chosen to further analyse the effects of rMMP-9 
in Exp. 3.
Differentiation of rMMP-9 and IB format effects. Aiming to determine whether the detected immune 
response triggered in the mammary gland by rMMP-9 IBs8 (Fig. 1) was only due to the nanoparticle format or 
whether the activity of the MMP-9 embedded in such nanoparticles was also relevant, as observed in mice14, an 
Exp. 3 was conducted. We compared the performance between rMMP-9 nanoparticles and the mutant and inac-
tive rMMP-9 counterpart at the established dose of 1.2 mg in bovine mammary gland. Surprisingly, there was no 
difference between the performance of inactive or active rMMP-9 nanoparticles in the recruitment of immune 
cells, neither in the general (i.e., WBC) nor in mononuclear or polymorphonuclear cells, being these levels much 
greater than in control quarters for both treatments (Fig. 3). As expected, the main recruited cells were neutro-
phils (determined as PMNCs, Fig. 3d), as they are the first immune cell to arrive to the inflammatory site, and in 
agreement with the behaviour previously observed in mice after the administration of rMMP-9 IBs14. However, in 
the mouse model, the inactive rMMP-9 nanoparticles only induced a slightly and transitory inflammatory effect, 
whereas the active form had a clear and sustained effect over time14. Thus, the performance of mutMMP-9 nano-
particles was different in the mouse intra-dermis model compared with the bovine mammary gland.
When other immune or involution parameters of bovine mammary gland were assessed, only in very few 
instances the active rMMP-9 nanoparticles had a slightly different performance compared to the inactive rMMP-9 
form. Concretely, BSA levels were greater at days 1 and 6 in quarters treated with active rMMP-9 nanoparticles 
(Fig. 4a), suggesting that MMP-9 had some activity behind the unspecific format effects. Also, Na+/K+ ratio 
increased at day 6 and this was sustained at day 9 (Fig. 4d). This indicates that the splitting time-point for both 
specific and unspecific effects of rMMP-9 IBs in bovine mammary gland at dry-off may occur later on, compared 
with the murine model14. However, during the analysed time in Exp. 3, and as observed for cellular recruitment, 
there were no rMMP-9-specific effects in lactoferrin nor in endogenous MMP-9 levels (Fig. 4b,c). Thus, these 
results confirm that the obtained effects in the bovine mammary gland were mainly due to the format (i.e., IB) 
but not due to the activity of the protein embedded in these nanoparticles. Again, this was an unexpected out-
come because, in mice, the effect of MMP-9 could be clearly differentiated already at day 1 after injections from 
the inflammatory consequences of the nanoparticle format14. The question now is what is causing such different 
effects between the two animal models? Divergence in the MMP-9 nanoparticle effects observed in mice model 
and in bovine mammary gland could be explained by important differences between the two in vivo models. On 
one hand, the mice model was knock-out for endogenous MMP-9, favouring a clear split between the MMP-
9-specific effect from the format-linked unspecific effect. Nonetheless, in bovine, mammary gland endogenous 
Figure 2. Mammary gland involution markers analysed from mammary gland secretions for the tested doses 
(0 –control–, 0.012, 0.12, and 12 mg) of inclusion bodies containing matrix metalloproteinase-9 along 0, 1, 2, 
3, 6, and 7 d post-infusion. Non-transformed means and SEM (error bars) are represented while P-values were 
obtained from transformed data, when necessary. Asterisks depict significant differences between treatments 
and the control group within time. (a) Somatic cell counts (SCC) are expressed in million (106) cells per mL (M 
cells/ml); P < 0.0001. (b) Bovine serum albumin (BSA); P < 0.0001. For differences between different treatments 
within each time point, see Table S2 in the Supplementary Material.
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MMP-9 seems not to have an important role at dry-off8. On the other hand, lactating and involuting mammary 
glands are very immune-active and responsive organs that, in fact, have been compared with strong mucosal 
immune programs15. This agrees with our results indicating that while in mice the nanoparticle unspecific effect 
was limited to 24 h, in the dairy cow mammary gland this was extended for a minimum of 9 d (except for Na+/K+ 
ratio, differenced at day 6, and the short specific effect in BSA). In this context, the same stimulus could trigger 
a greater inflammatory effect in cows than in rodents. Moreover, it has been demonstrated that soluble rMMP-9 
does not exert any effect on immune and involution parameters at the beginning of bovine dry period8. This find-
ing indicates that the protein embedded in the nanoparticles is not as relevant as in the mouse air pouches model, 
specifically designed to evaluate the MMP-9 activity and further infiltration of immune cells.
The effects of the IB format on the inflammation of a host were also previously studied by Torrealba et al. 
(2016a)16. They have demonstrated that protein nanoparticles could induce inflammation in Zebrafish and act as 
an adjuvant16, and this effect could be even increased through using nanoparticles composed by proteins with a 
relevant immune function, such as a cytokine17. Similar to results herein, Torrealba et al. (2016b) also described a 
dose-dependent effect when an unspecific protein like GFP was injected in Zebrafish, with a fast-induced immu-
nostimulating effect17. This is in agreement with other studies performed previously with LPS18,19, chitosan20, 
Panax ginseng extracts21,22, among others, in which a rapid immunostimulating effect is observed at dry-off.
Conclusions
Protein nanoparticles or inclusion bodies trigger a clear immunostimulant effect in the bovine mammary gland at 
dry-off. Matrix metalloproteinase-9 protein forming such nanostructures exerts no relevant effect in the context 
of the bovine dry-off. Thus, protein nanoparticles could be considered as an appealing strategy at bovine dry-off 
to accelerate this process and enhance the immune protection although MMP-9 protein itself does not provide 
any extra value during the first week of the dry period.
Materials and Methods
Bacteria strains and plasmids. Lactococcus lactis subsp. cremoris NZ9000 double mutant ClpP- HtrA- 
(clpP-htrA; EmR) strain23,24 (kindly provided by INRA (Jouy-en-Josas, France); patent n. EP1141337B1) was 
used to recombinantly produce the MMP-9 proteins. The genes encoding for an active bovine rMMP-9 fragment 
(Phe107 - Pro449, NCBI, NM_174744.2) and for the same rMMP-9 fragment with the E402Q single mutation25,26, 
which makes it an inactive rMMP-9 proteoform, were cloned in pNZ8148 plasmid (CmR) and transformed into 
Figure 3. Mammary gland cell populations analysed from mammary gland secretions for the 1.2 mg dose of 
inclusion bodies containing active (MMP-9 IBs) or inactive (mutMMP-9 IBs) matrix metalloproteinase-9 and 
control, along 0, 1, 3, 6, and 9 days-post infusion. All cell measurements are expressed in million (106) cells per 
mL (M cells/ml). Non-transformed means and SEM (error bars) are represented while P-values were obtained 
from transformed data, when necessary. Asterisks depict significant differences between treatments and the 
control group within time. (a) Somatic cell counts (SCC); P < 0.0001. (b) White blood cells (WBC); P < 0.0001. 
at P = 0.053. (c) Mononuclear cells (MNC); P < 0.0001. (d) Polymorphonuclear cells (PMNC); P < 0.0001. For 
differences between different treatments within each time point, see Table S3 in the Supplementary Material.
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competent L. lactis clpP-htrA cells. Both genes were fused to a His-tag in the C-terminal and were codon-opti-
mised (Geneart) for L. lactis11.
Protein Production in L. lactis. Both, active and inactive rMMP-9 were produced in L. lactis, which was 
grown under static conditions at 30 °C in M17 broth supplemented with 0.5% glucose, 5 µg/mL chloramphenicol 
and 2.5 µg/mL erythromycin. Cultures were re-inoculated to an initial OD600nm of 0.05 and protein expression was 
induced with 12.5 ng/mL nisin when the OD600nm reached values between 0.4 and 0.6. The recombinant proteins 
were produced along 3 h and bacteria were recovered by centrifugation at 6,000 x g for 30 min at 4 °C and stored 
at −80 °C until use.
Purification of IBs. Pellets from 50 mL culture were suspended in 30 mL PBS, frozen/thawed at −80 °C and 
disrupted with 3 French press (Thermo FA-078A) rounds at 1,500 psi, ice-coated, and with protease inhibitors 
(cOmplete protease inhibitor cocktail EDTA-free, Roche). After that a previously established purification pro-
tocol was applied as described27. Samples were tested for sterility by plating an aliquot in agar-M17 plates with 
0.5% glucose and incubating them overnight at 30 °C. Aliquots of rMMP-9 IBs and mutant inactive rMMP-9 IBs 
were tested for purity through SDS-PAGE electrophoresis and Coomassie blue staining (75.7% purity obtained 
for MMP-9 IBs and 70.3% for mutMMP-9 IBs), and were quantified by interpolation with the bands obtained by 
a solubilized rMMP-9 as the standard28, using ImageJ software (version 1.46r, U. S. National Institutes of Health, 
Bethesda, Maryland, USA). The activity of the MMP-9 IBs and the inactivity of the mutMMP-9 IBs, were vali-
dated in vitro both by zymography and DQgelatin (data not shown).
Protein infusions in cow mammary glands. Thirty-three multiparous pregnant Holstein cows in their 
second gestation, after 274 to 379 days in lactation and between 215 and 225 days of gestation, producing from 
25.5 to 43.7 kg of milk per day during the last week before dry-off, and with <200,000 somatic cell counts (SCC)/
mL in milk at dry-off per cow, were selected in this study. Cows were dried abruptly without any previous dietary 
nor milking routine intervention.
Experiments were performed in accordance with relevant guidelines and regulations under the evaluation and 
permission of the Ethical Committee of IRTA, protocol number 9705.
Figure 4. Mammary gland involution markers analysed from mammary gland secretions for the 1.2 mg dose of 
inclusion bodies containing active (MMP-9 IBs) or inactive (mutMMP-9 IBs) matrix metalloproteinase-9 and 
control along 0, 1, 3, 6, and 9 d post-infusion. Non-transformed means and SEM (error bars) are represented 
while P-values were obtained from transformed data when necessary. Asterisks depict significant differences 
between treatments and the control group within time. (a) Bovine serum albumin (BSA); P < 0.0001. (b) 
Lactoferrin (LF); P < 0.0001. (c) Endogenous MMP-9 was analysed only for selected times: 0, 1, 3 and 9 d post-
infusions; P < 0.05. (d) Na+/K+ ratio; P < 0.0001. For differences between different treatments within each time 
point, see Table S4 in the Supplementary Material.
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Three experiments were performed (Exp. 1, Exp. 2, and Exp. 3); 2 experiments aimed at optimizing the min-
imum effective protein dose to trigger an immune reaction in the mammary gland at dry off (Exp. 1 and Exp. 
2), and the third aimed at dissecting the effects triggered either by the protein activity or by the protein format 
(Exp. 3).
Udder quarter was used as an independent experimental unit and these were randomly allocated to treatments 
considering cows a random effect. A total of 46, 44 and 30 quarters used for Exp. 1, Exp. 2 and Exp. 3, respectively 
(2 animals were discarded due to mastitis and abortion, one for each Exp. 1 and Exp. 2). After the last milking 
before dry-off and just before protein infusions, 10 mL of mammary gland secretions (MGS) were collected from 
all quarters as a day 0 sampling.
In the first experiment (Exp. 1), a range of different doses of rMMP-9 IBs were infused into 10 quarters per 
treatment (due to mastitis, 1 quarter per treatment was discarded, except for control) through the teat canal using 
sterile blunt tip cannulas immediately after MGS collection at day 0. Namely, 1.2, 3, 6, and 12 mg of rMMP-9 
IBs suspended in 10 mL saline solution were infused, and 10 mL saline solution infusions was used as nega-
tive controls. Following infusions, all quarters were treated with broad-spectrum antibiotics (Mamyzin secado, 
Boehringer Ingelheim) following common production practices. At days 1, 3, 6, and 9 after protein infusions, 
10 mL of MGS were collected from each quarter. After the last sampling, all glands were sealed with teat sealant. 
All MGS were analysed fresh for SCC (n = 9 observations) as described below, and aliquots were stored at −80 °C 
until these were analysed for bovine serum albumin (BSA; n = 9), lactoferrin (LF; n = 8) and Na+/K+ (n = 9) 
levels.
The second experiment (Exp. 2) aimed at testing lower doses of rMMP-9. After collecting MGS at day 0, doses 
of 0.012, 0.12, and 12 mg of MMP-9 IBs and 10 mL of saline solution were infused into 11 quarters for each dose, 
and all of them were treated with antibiotics as described for Exp. 1. At days 1, 2, 3, 6, and 7 after infusions, MGS 
were obtained from each quarter and after the last collection, teat sealant was applied. The MGS were analysed 
fresh for SCC (n = 11), and BSA was analysed from aliquots after preservation at −80 °C (n = 11).
In the third experiment (Exp. 3), the minimum effective dose determined from Exp. 1 and Exp. 2 was used to 
compare the effects of the active and the inactive rMMP-9 IBs on the mammary gland at dry-off. Thus, rMMP-9 
IBs and inactive rMMP-9 IBs (mutMMP-9 IBs) at selected dose, and 10 mL of saline solution were infused into 10 
quarters per treatment and then quarters were treated with antibiotics following previously detailed steps in Exp. 
1. At days 1, 3, 6, and 9, after protein infusions, MGS were obtained and analysed fresh for SCC (n = 10) and for 
immune cell populations (n = 10), and aliquots were stored at −80 °C until analysed for BSA (n = 10), LF (n = 8), 
Na+/K+ (n = 10) and endogenous MMP-9 (n = 6).
Mammary secretion analyses. Somatic cell counts. Half mL of each MGS was mixed with half mL 
Dulbecco’s phosphate-buffered saline (DPBS; GIBCO), inverted several times and centrifuged at 1,000 x g for 
2 min at RT. Fat, located on top of the sample mixture, was removed by gently swirling a cotton swab around 
the top of the centrifuge tube. The supernatants were discarded without touching the cell pellets, and these were 
suspended in 1 mL DPBS and centrifuged again. Cells were washed twice, repeating the previous steps and were 
suspended in 0.5 mL DPBS. Cell suspensions were counted using a Scepter 2.0 Handheld Automated Cell Counter 
(Merck Millipore, Billerica, MA). Cells were diluted when appropriate to obtain a best resolution in the Scepter 
histograms, and particle counts with diameters below 6 µm were discarded for all samples.
Immune cell populations. After SCC, cell suspensions were stored overnight at 4 °C, and sent to the Veterinary 
Clinic Haematology Service at the Autonomous University of Barcelona (UAB, Barcelona, Spain) for the analyses 
of immune cell populations. Using a XN-1000 analyser (Sysmex), white blood cells (WBC), polymorphonuclear 
cells (PMNC) and mononuclear cells (MNC) were differentiated and counted following morphological measure-
ments by flow cytometry, selecting the body fluid mode.
Bovine serum albumin quantification. Bovine Serum Albumin (BSA) in MGS was quantified as described else-
where29. One mL of each MGS was centrifuged at 1,000 x g for 10 min at RT and fat was removed with a swab 
as detailed in the section for SCC determination. A commercial BSA was used as the standard curve and an 
eight-point serial dilution curve from 60 mg/mL was prepared. Two hundred µL of each supernatant were mixed 
in 450 µL dH20 and 450 µL of Bromocresol Green working solution (consisting in three parts succinic acid at pH 
4 and a part of bromocresol green sodium salt dissolved in 5 mM NaOH, and 0.8% Brij L23). The solutions for all 
samples and standards were centrifuged at 1,900 x g for 10 min at RT and 150 µL of each supernatant were plated 
by duplicate in flat bottom transparent 96-well plates and were read at 640 nm. Concentration of BSA in MGSs 
was interpolated to the 4-parametric standard curve.
Lactoferrin quantification. Whole MGS were analysed for lactoferrin concentrations using a bovine lactoferrin 
ELISA quantitation set (Bethyl Laboratories Inc., Montgomery, TX, USA). A commercial bovine lactoferrin cal-
ibrator was used as the standard curve, ranging from 500 to 7.8 ng/ml. After coating the plates with 0.01 mg/mL 
anti-bovine lactoferrin, followed by a blocking step as indicated in the manufacturer protocol, samples diluted at 
1/10,000 or 1/100,000 and standards were plated per duplicate and incubated for 1 h at RT. After several washes, 
HRP conjugated anti-bovine lactoferrin detection antibody was added at a final concentration of 0.01 µg/mL and 
incubated for 1 h at RT. Following several washes, 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate solution was 
added and reaction was stopped after 15 min with 0.18 M H2SO4. Plates were read at 450 nm and lactoferrin con-
centrations were interpolated from the 4-parametric standard curve.
Sodium and potassium quantification. All samples were analysed for Na+ and K+ concentrations at the Chemical 
Analysis Service at the UAB. An aliquot of 0.1 g of MGSs was diluted in Triton X-100 0.1% (v/v). Clotted samples 
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were previously digested in HNO3 concentrate in a Ultrawave microwave digestion system (Milestone). Na+ and 
K+ levels were determined by inductively coupled plasma-Optical emission spectrometry (ICP-OES; Optima 
4300DV, Perkin-Elmer, Waltham, MA, USA).
Endogenous MMP-9 zymography. Skimmed MGS were quantified for endogenous MMP-9 activity through 
zymography analysis. Solubilized MMP-928 was used to prepare an eight-point standard curve ranging from 
400 to 25 ng. Sample supernatants were diluted 1/10 and diluted samples and standards were loaded with 
non-denaturing loading buffer into 10% SDS-PAGE gels containing 1% porcine gelatine. Electrophoresis was 
run at constant 50 mA and gels were washed twice in 2.5% Triton X-100, once in distilled water, and were incu-
bated in static overnight at 37 °C in developing buffer containing 50 mM Tris pH 7.5, 200 mM NaCl and 10 mM 
CaCl2. Afterwards, Coomassie Blue staining was used to dye the gels for 2 h at RT and these were distained in a 
methanol-acetic solution. Degradation bands were analysed using ImageJ software and MMP-9 activity quantifi-
cation was interpolated from the solubilized MMP-9 standard curve.
Statistical analyses. A total of 46, 44, and 30 quarters were used in Exp. 1, Exp. 2 and Exp. 3, respec-
tively. Quarters were randomly allocated to treatments, considering cows a random effect. For immune cell pop-
ulations, outliers considered as 2-times standard deviation were discarded. Variables were log-transformed in 
Exp. 1, Exp. 2 and Exp. 3, or root-transformed for Na+/K+ in Exp. 1, to normalize data when necessary. Data 
were analysed using a fixed-effects model using SAS 9.4 (SAS Inst. Inc., Cary, NC). Time, dose and the inter-
action between time and dose were included the model, with quarters nested within cows and cows as ran-
dom effects. Time was included as a repeated measure and for each analysed variable, quarters within cows (the 
error term) was subjected to 2 variance-covariance structures: compound symmetry and autoregressive order 1. 
The covariance structure that yielded the smallest Schwarz’s Bayesian information criterion was considered the 
most desirable analysis. Means and standard deviations represented in graphs correspond to non-transformed 
or back-transformed data, while P-values and asterisks correspond to the output from transformed data when 
required. Additional information on the differences among treatments within each time point can be found in 
the Supplementary Material.
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